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Some side effects of heparin, heparinoids, and their antagonists 
Effects of heparin, heparinoids, and their antagonists, other than actions on blood coagulation 
and lipemia clearing, are described. Many, if not all, of these properties are probably 
related to the unusual structure and high-charge density of these macromolecules. 
Some may have therapeutic utility. 
William W. Coon, M.D., and Park W. Willis, III, M.D. Ann Arbor, Mich. 
Departments of Surgery and Medicine, University of Michigan 
Since its discovery fifty years ago, 
heparin has been extensively used as an 
anticoagulant and, in recent years, as an 
agent to facilitate more rapid clearing of 
lipemic plasma. These functions of heparin 
have been adequately reviewed in the re-
cent past. This monograph lists some of 
the side effects of heparin which are not 
so well known. Some may ultimately be 
shown to be directly related to the anti-
coagulant effect of heparin but, if so, this 
association has not yet been proved. 
Several of these effects have been observed 
only in vitro, and to our knowledge studies 
to document whether or not they persist in 
vivo have not yet been carried out. A few 
may have therapeutic applications. Knowl-
edge of others may aid in the correct inter-
pretation of extraneous effects which might 
occur during heparin therapy. 
Formation of "complexes" 
One of the earlier known side effects 
of heparin was demonstration of its ability 
to form stable salts with many pro-
teins.31 , 54, 172 Over thirty years ago, Fischer 
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and Astrup56 demonstrated that these salts 
partially dissociate according to mass law 
as long as the product remains in solution; 
this has been confirmed by Jaques.100 Com-
plexing with heparin has been observed 
not only with proteins and peptides (silk 
peptone, gelatin, clupein, salmine, his tones 
from thymus and blood, hemoglobin, egg 
albumin, casein, serum proteins, liver pro-
teins, thromboplastins, enzymes, and so 
forth) but also with organic bases (benzi-
dine, quinine, brucine, and piperidine) and 
basic dyes (thionine, toluidine blue, and 
others). Although optimal combination of 
heparin with protein occurs near the iso-
electric point, it is possible for heparin to 
combine with proteins on the alkaline side 
of their isoelectric point. Dissociation of 
these compounds is markedly affected by 
pH and ionic strength.10o Jaques has made 
reference to the difficulty of confirmation 
of reports by others regarding the inhibi-
tory effect of heparin on certain proteins 
because reproduction of relative concen-
trations of heparin, the protein under 
study, of other proteins, pH, ionic strength, 
and so forth is often difficult. The early 
work on complex formation by heparin 
has been summarized by Jorpes. 106 Studies 
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of charged polyglucose derivatives add to 
our understanding of the mechanism of 
effect of heparin and heparinoids. Macro-
cationic substances with enzymatic activity 
(hyaluronidase, ribonuclease, and lyso-
zyme) are reversibly inhibited by synthetic 
sulfated polysaccharides; these enzymes 
can be reactivated by addition of other 
cationic agents such as sodium ion or pro-
tamine. Highly substituted sulfates are the 
most effective enzyme inhibitors, while 
sulfates of similar molecular size but lower 
charge density have less inhibitory activity. 
The product with highest branching and 
charge density is about five times as active 
as heparin in inhibiting ribonuclease. These 
derivatives also precipitate other basic pro-
teins (protamine, an ACTH preparation, 
cytochrome C, and serum albumin) from 
aqueous solution at low pH and salt con-
centration.15l 
The electric charges of heparin prepara-
tions are proportional to their content of 
ester sulfate; cataphoric mobility is of the 
order of 17 to 19 x 10-5 cm.2 V-I sec-1 at 
pH 2 to 8; heparin apparently has the 
strongest electric charge of any organic 
compound normally found in the human 
body.219 
Macroglobulins isolated from patients 
with macroglobulinemia are precipitable 
by heparin but not by chondroitin sul-
fate. 149 Heparin and heparinoids precipitate 
fibrinogen, particularly at low tempera-
tures.9. 174. 194. 204 A stoichiometric relation-
ship exists between heparin and fibrino-
gen65 during the process of precipitation, 
as it does for other heparin-protein com-
plexes.56 Beta liproproteins are also pre-
cipitated by heparin. 25 
Heparin, along with other anionic poly-
saccharides, acts as an ion exchanger.51 . 
182, 183, 211 The order of increasing cation 
affinity, when acid mucopolysaccharides 
are treated as ion exchangers, varies 
for heparin, heparin monosulfate, and 
chondroitin sulfate.45 The order of increas-
ing cation affinity for heparin is: sodium, 
potassium, magnesium, strontium, barium, 
and calcium; the differences in order 
Clinical Pharmacology 
and Therapeutics 
of affinity between heparin and other 
anionic polysaccharides have been attrib-
uted to differences in structure of these 
several molecules. Their association with 
cations in solution is thought to be of elec-
trostatic rather than covalent type. The 
affinity of acid mucopolysaccharides for 
calcium decreases in the order: heparin, 
chondroitin sulfate B, chondroitin sulfate 
A, and hyaluronic acid.24 
The effect of heparin upon cellular cal-
cium has been studied in vitro in Ehrlich 
ascites tumor cells labeled in vivo with 
isotopic Ca4li ; no change in calcium content 
of cells was observed when cells were in-
cubated in solutions containing up to 0.6 
mg. heparin per milliliter.205 Heparin does 
increase Rb86 outflow from the diaphrag-
matic muscle of rats, an effect similar to 
that produced by reduction in concentra-
tion of calcium ions. 28 Potassium exchange 
is affected in a similar manner.86 
Heparin is a potent inhibitor in vitro of 
fumarase,57 lysozyme,115 and tissue ribonu-
cleases and desoxyribonucleases.128, 178, 207 
Significant inhibition of acid and alkaline 
ribonucleases of hepatic origin has been 
obtained one hour after heparin injection 
in vivo in white mice.129 Heparin, but not 
hyaluronic acid or polyglutamic acid, in-
hibits adenylic deaminase in vitro; no 
inhibition of phosphoenolpyruvic kinase, 
hexokinase, phosphoglyceric mutase, or 
enolase has been observed!' Heparin is a 
nonspecific and apparently competitive 
inhibitor of hyaluronidases of diverse 
origins. 77 ,95 Both inhibitor and substrate 
compete for the same energy sites; an in-
crease in ionic strength decreases the 
inhibitory effect of heparin and chondroitin 
sulfate B.95 Serum beta-glucuronidase 
activity is decreased 43 to 64 per cent in 
human postheparin sera.14 Beta-glucuroni-
dase shows a two thousand fold greater 
affinity for heparin than for phenol-
phthalein .beta -glucuronide. 27 Nonspecific 
stimulation of tyrosine-alpha ketoglutarate 
transaminase activity in vivo by heparin, 
chondroitin sulfate, and a number of other 
agents has been observed. This stimulation 
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is dependent upon intact adrenal glands 
or upon the presence of hydrocortisone.138 
Heparin is thought to function in an ion-
exchange capacity in its complexing with 
histamine. In vitro, heparin binds hista-
mine4, 12, 167 and also apparently inhibits 
release of histamine from cells to plasma.44 
Histamine is selectively bound by heparin 
in the presence of equivalent amounts of 
cadaverine, serotonin, or epinephrine but 
is displaced by multivalent ions in prefer-
ence to univalent ions,119 One mole of 
heparin will bind 21.5 to 22.0 moles of his-
tamine.119,2l6 However, heparin, even in 
high doses, has little effect on the actions 
of histamine in vivo. 26 , 132 
Heparin inhibits gastric secretion from 
Heidenhain pouches in dogs after stimula-
tion by food or by exogenously adminis-
tered histamineY' However, whether this 
suppression of gastric secretion is secon-
dary to complexing with histamine in vivo 
is not yet known. Heparin, chondroitin 
sulfate, and sodium polyhydromannuronic 
acid sulfate, but not hyaluronic acid, in-
hibit pepsin in vitro. Chondroitin sulfate, 
which markedly reduces the number of 
gastric ulcers in Shay rats, has been shown 
to inhibit pepsin in vivo as well.135 
The nonspecific complexing of heparin 
with cationic macromolecules has been used 
experimentally to protect mice from a lethal 
dose of polymyxin; intraperitoneal admin-
istration of heparin is more effective than 
an intravenous dose.90 Sulfate and carboxyl 
derivatives of polyglucose have a similar 
protective effect against polymyxin and, to 
a lesser degree, neomycin and strepto-
mycin.152 Heparin apparently counteracts 
the acute toxic effects of neomycin with-
out producing an equivalent loss in anti-
biotic activity. 89 
In recent years, further data on "com-
plexing" by heparin in vitro have been re-
ported. This complexing might have con-
siderable physiologic significance if it were 
shown to occur in vivo as well. The anti-
curariform action of heparin and many 
heparinoids has been related both to 
magnitude of electronegative charge and 
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to molecular size.32 Heparin has been 
shown to dissociate the insulin complex in 
vitro, freeing insulin from its basic pro-
tein. 76 Heparin also complexes with 
kallidin; the complex may be split with 
compound 48/80. 217 Heparin and dextran 
sulfate accelerate plasma kinin formation 
in vitro, as reHected by increased oxytocic 
activity, pOSSibly by blocking the effect of 
an inhibitor; protamine sulfate and hexadi-
methrine bromide but not toluidine blue 
block kinin formation both in the presence 
and absence of heparin but do not inter-
fere with uterine response to preformed 
kinin. G Hexadimethrine apparently inhibits 
kinin formation by an inhibition of Hage-
man factor which normally plays a role 
in kinin formation by activating a kinin-
forming enzymeY 
Heparin also complexes with trypsin; the 
heparin-trypsin complex may be disso-
ciated by acidification to pH 3 for 30 
minutes with complete recovery of tryptic 
activity. Heparin does not inhibit chymo-
trypsin. 94 Although heparin completely pro-
tects rats against LD99 doses of trypsin 
intravenously, this effect may be related 
to the anticoagulant action of heparin, 
blocking the coagulant properties of 
trypsin. 43 
In the past few years, the relationship 
of heparin to the plasmin-enzyme system 
has received a great deal of interest and 
attention. The current consensus of opinion 
is that, while large amounts of heparin in-
hibit plasmin in vitro and in vivo, smaller 
amounts stimulate fibrinolytic activity if 
a factor from the albumin fraction of 
plasma is also present. 8 , 33, 78, 111, 112, 122, 199 
Heparin 74 and a heparinoid (Ateroid) 121 
increase fibrinolytic activity which has de-
creased in the presence of alimentary 
lipemia; Ateroid does not affect the plas-
min-enzyme system in the absence of 
alimentary lipemia. Fibrinolytic activity in 
guinea pig serum is increased in vitro by 
heparin, hyaluronic acid and chondroitin 
sulfate, dextran sulfate, and several other 
synthetic sulfated polysaccharides; neutral 
polysaccharides have no effect. Total activ-
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ity is dependent upon pH and concentra-
tion of acid polysaccharide. Some of the 
most potent stimulators of fibrinolytic activ-
ity have no anticoagulant activity. In higher 
concentrations, acid polysaccharides ap-
parently precipitate inhibitors of fibrinol-
ysis. Olesen'62 has suggested that the 
mechanism of action of these acid poly-
saccharides is polyanionic in character, and 
that they interact with an inactive complex 
in serum to release a plasminogen activa-
tor. The effects of these acid polysaccha-
rides can be reversed by addition of 
cationic agents. 
Addition of heparin in low concentration 
to whole blood, serum, or oxalated plasma 
increases the rate of hydrolysis of benzoyl-
I-arginine ethyl ester.59 Since this ester 
is a substrate for plasmin and since larger 
amounts of heparin inhibit hydrolysis, this 
increase in enzymatic activity may be 
mediated through the effect of heparin 
in stimulating fibrinolytic (plasmin) activ-
ity. In vitro, in high concentration, heparin 
inhibits plasminogen activation by strepto-
kinase or urokinase but not the fibrinolytic 
effect of Aspergillus protease. s, 92 
Heparin has not been shown to have a 
demonstrable effect upon fibrinolytic activ-
ity in vivo. Heparin injections in healthy 
male volunteers previously given a bac-
terial pyrogen did not alter fibrinolytic 
activity.93 
Anticomplementary effect; treatment of 
hyperimmune diseases 
In vitro, in a sheep red-cell system, 0.04 
to 0.06 mg. of heparin will inhibit one unit 
of complement from guinea pig serum; this 
inhibitory effect is considered to be on 
the third component of complement.46 The 
anticomplementary effect of heparin and 
several heparinoids (dextran sulfate, chlo-
razol pink, and polyanethol sulfonate) 
does not correlate with relative anticoagu-
lant potency.127 Heparin treatment of 
guinea pigs has no effect upon syntheSis 
of antibody induced by immunization with 
human serum.96 Local or parenteral 
injection of heparin reduces the in-
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tensity of ocular inflammation produced 
by horse serum or tuberculin hypersensi-
tivity.IS, 19, 210, 223, 224 
Heparin, heparinoids, and salts of a 
rare earth (neodymium) inhibit in vitro'97 
and in vivo'9s hemolysis produced by anti-
erythrocyte antibodies in rabbits. This 
effect is not related to anticoagulant activ-
ity since germanin and Treburon (a sul-
fonated pectin) which are weak anticoagu-
lants have higher anticomplementary 
activity than heparin. Hemolysis induced 
by cobra venom is also inhibited, presum-
ably by suppression of lysolecithinase. None 
of these agents has an effect on adsorption 
of amboceptor on the erythrocyte, on 
agglutination, or on hemolysis by simple 
lysins (saponin and digitonin).197 Heparin 
has a beneficial effect in vitro and in vivo 
in acquired hemolytic anemia in man; the 
direct Coombs reaction decreases in titer 
and becomes negative, and plasma hemo-
globin, serum bilirubin, and osmotic fra-
gility decrease. SS, 164, 179, lSI Similar inhibi-
tion of hemolysis has been reported in 
patients with paroxysmal nocturnal hemo-
globinuria.6o 
In the light of modern knowledge, the 
anticomplementary effect of heparin is not 
a convincing explanation for the beneficial 
effect of heparin in acquired hemolytic 
anemia. 'so Fifteen thousand units of 
heparin injected subcutaneously in normal 
subjects will depress complement activity 
about 40 per cent for less than 2 hours. 
Since 5,000 to 10,000 units per 24 hours 
will achieve a beneficial effect in the treat-
ment of hemolytic anemia, and protamine 
which is a more potent anticomplementary 
agent has no effect, this cannot be the 
mechanism of action. Studies in vitro of 
the effect of heparin on autoantibodies and 
sensitized red cells from patients with ac-
quired hemolytic anemia have shown that 
heparin acts on red blood cells and auto-
antibodies directly, and that complement 
plays no part. 'SO 
Pretreatment with heparin protects 
guinea pigs and rabbits from anaphylactic 
shock.102, 103, 124, 220 Heparin pretreatment 
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also suppresses anaphylactic shock in sensi-
tized pigeons124 and the Arthus phenom-
enon in sensitized rabbits.133 In anaphylac-
tic shock, heparin prevents a decrease in 
platelets and an increase in 5-hydroxy-
tryptamine in whole blood.102, 103 Heparin 
may act by inhibiting the ability of plate-
lets to absorb or release 5-hydroxy-
tryptamine. Heparin also prevents the de-
crease in platelet count accompanying 
allergic reactions to a specific antigen and 
prevents most of the local response to 
intradermal injection of a specific antigen 
in man; this antiallergic effect of heparin 
has also been explained on the basis of 
inhibition of release of 5-hydroxytrypt-
amine.104 Heparin does not block histamine 
shock in the mouse, nor is the contracture 
of isolated ileal segments from sensitized 
animals elicited by antigen or histamine in 
vitro inhibited.110 
Heparin has also been shown to prevent 
or partially suppress the manifestations of 
experimental nephrosis in rats,r 77 nephritis 
in rabbits79, 80, 118 and guinea pigs191 pro-
duced by antikidney serum, and cortisone 
nephropathy in the rabbit.176 Experimental 
nephrosis in dogs and rats is not affected 
by heparin treatment.214 
Reversal of the L.E. (lupus erythema-
tosus) test in vivo in several patients re-
ceiving injections of heparin has been 
reported; inhibition in vitro is also demon-
strable and may be related to binding of 
complement.85 
Effect upon ACTH and lymphocytic and 
granulocytic response 
The possible antagonistic effects of 
heparin and ACTH have not been clearly 
defined. The inhibitory effect of ACTH on 
heparin appears to be spurious. Not all 
preparations of ACTH have an inhibitory 
effect.16 The influence of ACTH on throm-
bin clotting time of heparinized plasma 
may be due to phenolic contaminants or 
additives in ACTH preparations which 
produce partial inactivation of heparin co-
factor. 50 Heparin-neutralizing substances 
isolated from preparations of ACTH and 
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heparin inhibitors (protamine, toluidine 
blue, methylene blue, fuchsin, and methyl 
violet) stimulate motor activity of the iso-
lated guinea pig uterus; heparin has no 
direct effect on spontaneous motor activity 
of the uterus but inhibits the effect of 
these other agents.17 
The inhibitory effect of heparin on cer-
tain physiologic responses to ACTH may 
be valid. Heparin does not alter the mag-
nitude of depletion of adrenal ascorbic 
acid produced by various stress-producing 
agents154 but actually potentiates the de-
crease in thymic weight produced by 
ACTH.37 Protamine sulfate, however, has 
been reported to suppress the effect of 
ACTH on depletion of adrenal ascorbic 
acid.52 Heparin pretreatment prevents the 
decrease in total leukocyte and eosinophil 
counts in rats given sodium salicylate, 
epinephrine, or ACTH but, in moderate 
doses, has no effect on cortisone-treated 
animals.82 Other investigators have shown 
an inhibitory effect of larger doses of 
heparin on cortisone-induced leukopenia 
as well. 81 Guinea pigs injected with hepa-
rin daily for 5 days develop a rise in 
eosinophil counts to several times basal 
valuesY Heparin may mobilize eosinophils 
from the intestinal wall since perfusion of 
isolated dog intestine with heparinized 
blood results in a decrease of eosinophils 
in intestinal wall and an increase of these 
cells in the perfusate.66 Heparin does not 
inhibit the de granulating effect of ACTH 
on gastric mucosal mast cells or its destruc-
tive effect on tissue eosinophilia.169 A single 
intravenous injection of 20,000 I.U. of hepa-
rin produces in normal man an increase 
in eosinophils which lasts for more than 
4 hours.21 An intravenous injection of 
heparin in rabbits brings about a re-
duction in the number of circulating 
basophils.168, 206 This phenomenon could 
not be reproduced in normal human 
males.23,206 
Intravenous heparin produces definite 
lymphocytosis in the calf; mobilization of 
lymphocytes from lymph nodes, rather than 
an actual increase in production, is favored 
384 Coon and Willis 
to explain this phenomenon.99 Heparin in-
jections in rats are followed by not only a 
significant increase in lymphocytes but in 
neutrophils as well; the lymphocytosis is 
predominant, however. When heparin and 
hydrocortisone are given simultaneously, 
heparin blocks the lymphopenic effect of 
hydrocortisone, and hydrocortisone in-
hibits the effect of heparin on the neutro-
phil count."66 
Effect on the vascular system, blood 
flow, and oxygen consumption 
Clinical observations from Germany of 
apparent beneficial effects of heparin in 
the treatment of hypertension have been 
followed by several experimental studies. 
Heparin in doses which do not appreciably 
affect clotting time lowers the blood pres-
sure in DOCA-induced hypertension or 
nephrogenic hypertension in rats; the de-
pression in blood pressure persists if hepa-
rin treatment is continued.84, 114, 148 If, 
however, hypertensive rats are injected 
intraperitoneally with water to damage 
mast cells, the hypotensive effect of hepa-
rin is very transitory. Similar inhibition of 
heparin effect on blood pressure is ob-
served after pretreatment with large doses 
of a histamine liberator (compound 48/ 
80).114 Although hypertensin is bound to 
heparin in vitro,lOl heparin-treated hyper-
tensive rats respond like normal rats to 
injections of angiotensin amide, renin, or 
epinephrine.83 
Some controversy exists concerning the 
effect of heparin on cardiac activity. Hepa-
rin inhibits the contraction of isolated frog 
hearts, apparently having a primary effect 
on heart muscle itself since atropine and 
epinephrine do not reverse this action. 
Since calcium, however, induces recovery, 
this effect may be related to the action of 
heparin as an ion exchanger in binding 
calcium. Inhibition of cardiac activity with 
a high concentration of calcium is reversed 
when heparin is added. 39 Heparin inhibits 
cardiac contractility even when desul-
furated. 28 Glucuronic acid, but not gluco-
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samine, has the same effect. 39 Protamine 
sulfate produces an inhibition of cardiac 
contraction which is not effectively re-
versed by calcium.39 
Large doses of heparin increase myo-
cardial contractile force. 73 Preparations of 
heparin which have a greater concentra-
tion of amino-containing compounds than 
that expected on the basis of the content 
of glucosamine cause a contraction of 
guinea pig ileum; this smooth muscle con-
tractility, which could have been secondary 
to contamination with conjugated hista-
mine, was different in type from that in-
duced by histamine and was not prevented 
by an antihistamine.72 This contraction of 
smooth muscle has been explained as prob-
ably related to contaminating polypeptides 
which have been shown to be present. 
Chondroitin sulfate and hyaluronic acid 
have no significant effect as smooth muscle 
stimulators. 
Heparin inhibits serotonin-induced activ-
ity in an in vitro rat colon preparation and 
the vascular depressant effects of serotonin 
in cats.193 However, heparin has no con-
sistent effect on forearm blood How in 
humans and does not block the vascular 
effects of serotonin injections.126 These ex-
periments do not exclude the possibility 
that heparin might prevent the release of 
serotonin from platelets or other cellular 
sources. 
ConHicting studies have appeared con-
cerning the effect of heparin on blood 
viscosity. Heparin in increasing amounts 
has been reported to decrease the apparent 
viscosity, pseudoviscosity, and yield value 
of whole blood, plasma, or serum. 35 How-
ever, the magnitude and significance of any 
decrease in viscosity is still controversial,70 
and recent studies do not confirm this 
finding. 61 
Intravenous injections of heparin in 
guinea pigs in doses comparable to or 
higher than those utilized in man have no 
effect on vasodilatation or capillary per-
meability. Vasodilatation is observed after 
intra-arterial heparin but not after the 
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intra-arterial injection of several hepa-
rinoidsYs Heparin has no significant effect 
on cerebral blood flow, cerebral oxygen 
utilization, or cerebral vascular resistance 
in man.20~ In controlled studies of subjects 
with intermittent claudication of the lower 
extremities, heparin has brought about no 
improvement other than an anticipated 
"placebo effect" observed in controls as 
well.158. 1 "2 
Although heparin does have an im-
mediate effect on increasing coronary blood 
flow in dogs, intravenous injection of bis-
hydroxycoumarin has a similar prompt 
effect. The mechanism of action of either 
of these agents has not been clarified; no 
change in blood viscosity was detected. 02 
An increase in survival time has been 
observed in heparinized rats maintained in 
an environment of pure nitrogen; no change 
in total oxygen consumption was noted. 109 
Following heparin administration the 
blood, brain, cerebrospinal fluid, and 
vitreous humor barriers become more per-
meable to p32 and to penicillin. 1 13 The 
erythrocyte content of lymph also in-
creases. 226 The mechanism of this effect 
has not been defined. Saxl and associates1S4 
have shown that many polyelectrolytes 
with a negative charge disperse red blood 
cells, while those with a positive charge 
induce agglutination. Heparin is adsorbed 
on the surface of the erythrocyte, in-
creasing electrostatic repulsion between red 
blood cells and thus increasing suspension 
stability of the blood. ,s4 
Effect upon growth of bacteria, yeasts, 
and viruses 
Heparin in a protein-free medium is 
bacteriostatic but not bacteriocidal at con-
centrations of 100 parts per million or 
greater when tested against Bacillus 
stewarti or Micrococcus pyogenes var. 
aureus. Heparin failed to inhibit budding 
in yeasts at concentrations of lO,OOO parts 
per million. 215 Heparin produces bacterio-
stasis in an organic medium only if blood 
from the region of an injury or pus is 
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added to a culture of Staphylococcus 
au reus containing heparin.196 Warren and 
Graham2l " have postulated that these find-
ings support the premise that heparin con-
tains more than one bacteriostatically active 
component, one not requiring a cofactor 
but rendered inactive by possible com-
plexing with basic proteins, and the other 
requiring a cofactor but active in the pres-
ence of other proteins. 
Protamine sulfate also has a bacterio-
static but not a bacteriocidal effect against 
many bacteria in neutral or acid media.189, 
215 Since added ribonucleic acid has been 
shown to block this bacteriostatic effect, 
Wolff and Brignon221 have proposed that 
the effect of protamine may be to combine 
with ribonucleic acid, thus blocking cellu-
lar division. 
Heparin and certain other sulfated muco-
polysaccharides inhibit multiplication of 
some viruses in culture.1, 156. 200. 201 Chon-
droitin sulfate has no effect on virus replica-
tion while dextran sulfate, heparin, and a 
sulfated agar polysaccharide all produce 
significant inhibition. 20o While dextran 
sulfate inhibits multiplication of encephalo-
myocarditis, Coxsackie A 9, and herpes 
viruses, the plaque-forming ability of at-
tenuated types 1 and 2 poliovirus is actually 
enhanced. 201 Heparin has no effect on 
mumps, Newcastle disease, measles, vac-
cinia, adeno I and II, Coxsackie B 5, and 
ECHO 9 and 13 viruses.209 Heparin de-
creases the titer of the infectious nucleic 
acid prepared from the lactic dehydrogen-
ase agent but has no demonstrable effect on 
the intact virus.160 The growth of fibroma 
virus-induced tumors in the rabbit is in-
hibited by heparin and polyanethol sul-
fonate.'" Heparin therapy has also shown 
some promise in the clinical treatment of 
dermatitis herpetiformis. 3 Heparin is 
thought to inhibit virus multiplication by 
preventing the attachment of virus to 
cells;209 dextran sulfate may have a dif-
ferent mechanism of action. 20o Various 
polyanions with strong electronegative 
charges produce viral inhibition; molecular 
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size and the degree of sulfation appear to 
influence the magnitude of the effect.157 
Effect upon other cells and collagen 
The development of the fertilized eggs 
of certain marine organisms is inhibited by 
heparin, toluidine blue, and Thrombocid 
(a heparinoid),87. 150 
Several investigators have reported that 
heparin has a strong growth-inhibitory ef-
fect on both fibroblasts 175 and chondro-
blasts55 in tissue culture although this find-
ing could not be duplicated with strain L 
fibroblasts.ll7 No inhibition of growth of 
three strains of human cells (one from a 
nonneoplastic source), grown directly on 
glass in a fluid medium, was observed after 
exposure to high concentrations of heparin; 
Lisnell and Mellgren137 have proposed that 
other reports regarding growth-inhibiting 
action of heparin in vitro may have re-
sulted from differing tissue culture tech-
niques. Other investigators have grown 
cells in a plasma coagulum; the effect of 
heparin may have been related to the 
stimulation by heparin of fibrinolytic de-
struction of the coagulum, causing the 
cells to lose support and thus a suitable 
medium for growth. 
Incubation of rabbit bone marrow cells 
in concentrations of heparin from 0.025 to 
1.0 mg. per milliliter is not followed by a 
significant decrease in synthesis of desoxy-
ribonucleic acid. Phenol in low concentra-
tion does depress DNA synthesis. Lochte, 
Ferrebee, and Thomas" 39 speculate that 
phenol added as a preservative in heparin 
solutions may be one factor influencing 
prior reports of the inhibitory effects of 
heparin. This effect of phenol is only ob-
served, however, when the concentration of 
phenol is greater than 0.12 mg. per milli-
meter. Although heparin does not appear 
to have an effect upon synthesis of desoxy-
ribonucleic acid, there is considerable evi-
dence that it does produce solubilization 
of nucleoprotein. Decreases in mitotic ac-
tivity in hanging-drop cultures of embry-
onic chick heart after the addition of hep-
arin have been related to the histochemical 
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demonstration of granules of ribonucleo-
protein which accumulate in the cytoplasm 
of these cells." 65 Heparin in a low concen-
tration increases the viscosity of a rat liver 
brei. This increased viscosity is prevented 
by removal of the nuclear fraction from 
the brei; heparin increases the viscosity 
of nuclear suspensions, and DNA can be 
demonstrated in the centrifugate. Similar 
experiments with mitochondria have shown 
that heparin causes the release of ribo-
nucleic acid from this fraction. Anderson 
and Wilbur5 propose, on the basis of these 
experiments, that heparin displaces nucleic 
acids from basic proteins and that this 
may be the mechanism of the inhibitory 
effect of heparin upon cell division. 
Addition of heparin before or after 
freeze-thaw-induced structural alterations 
of Littre ascites tumor cells brings about 
dramatic fading of nuclei. No effect is seen 
after addition of heparin to unfrozen con-
trol samples. After injury of the plasma 
membrane by freezing and thawing, hep-
arin is able to enter the cell and produce 
solubilization of nucleoprotein. Similar ef-
fects are seen with fresh nuclei isolated 
from chick erythrocytes. The gellike vis-
cosity of the medium surrounding frozen-
thawed preparations of ascites tumor cells 
or chicken erythrocytes is immediately 
liquefied by desoxyribonuclease. Chon-
droitin sulfate A has no effect in this sys-
tem."90 
Heparin is taken up by cells in tissue 
culture, producing various cytologic effects 
on hamster sarcoma, depending upon its 
concentration in the culture medium. At 
100 and 1,000 gamma per milliliter, it 
stimulates the appearance of cytoplasmic 
microvilli. At 1,000 gamma per milliliter 
an alteration in neutral-red staining is 
observed; at 2,000 gamma per milliliter 
vital staining disappears. Cytoplasmic and 
nucleolar vacuolation and abnormal mitotic 
figures are also observed. 36 These effects 
may be related to other observations con-
cerning the effect of heparin upon solubil-
ization of ribonucleoprotein and desoxy-
ribonucleoprotein. 
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Heparin is a potent inhibitor of the up-
take of labeled serum-bound lipids by 
human and animal epithelial cells. This 
appears to be due to a physicochemical 
effect of heparin upon the cell membrane 
since other anions or cations produce sim-
ilar or opposite results, depending exclu-
Sively upon their charges.131 This finding 
may be of considerable importance in 
pointing to a potential action of heparin 
and other anionic macromolecules in in-
Ruencing mechanisms of cellular transport. 
Heparin also stimulates pinocytosis in 
mouse fibroblasts 42 and induces the forma-
tion of pseudopodia in Amoeba proteus 
when a fine pipette containing 3 x 10-5 
molar heparin is held near an ameba. Hep-
arin apparently depolarizes the membrane 
of the ameba; this is thought to be the 
basis for stimulation of pseudopod forma-
tion.15 
ConRicting reports have appeared con-
cerning the effect of heparin upon mitotic 
activity of cells. Heparin injected intra-
peritoneally in rats reduces the number of 
mitoses in gastric epithelium but not in 
duodenal epithelium.170 Intraperitoneal in-
jection of heparin results in marked stimu-
lation of mitotic activity and increase in 
desoxyribonucleic acid synthesis in paren-
chymal liver cells of normal rats; heparitin 
sulfate has a similar effect. Chondroitin 
sulfate B displays lesser activity while 
chondroitin sulfate A, chitin sulfate, and 
polystyrene sulfonate have no stimulatory 
effect.229 This action of heparin may be 
responsible for contradictory reports con-
cerning the presumed stimulatory effect of 
plasma from hepatectomized rats on mitosis 
of liver cells in normal rats, since this 
effect is not observed when plasma is 
collected in citrate rather than heparin 
solutions.228 
Collagen fibers are formed immediately 
in vitro by the action of heparin (1: 80,000) 
or Paritol (a heparinoid, 1: 40,000) on solu-
tions of collagen. Glucuronic acid, glucos-
amine, and N-acetyl glucosamine have no 
effect.153 Other investigators have reported 
that low concentrations of heparin retard 
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fibril formation in solutions of acid-soluble 
collagen at pH 7. Chondroitin sulfates A 
and C accelerate fibril formation. Chon-
droitin sulfate B and hyaluronic acid have 
no effect.2"2 
Effect upon the growth of transplan-
table tumors 
Since heparin is most effective if given 
prior to and again immediately after tumor 
inoculation, it may act to inhibit successful 
implantation of tumor cells.GD This effect 
of heparin may be related to its anticoagu-
lant effect in suppressing fibrin formation, 
but documentation of this fact, as far as 
inhibition of the growth of a primary tumor 
inoculum is concerned, has not yet been 
established. 
Preliminary exposure of sections of rat 
carcinoma to a solution of heparin for 22 
hours prior to transplantation has com-
pletely suppressed tumor development.G7 
Zakrzewski,227 studying thousands of ani-
mals with rat and mouse sarcoma, has 
shown that heparin injected intravenously, 
intraperitoneally, or into tumor tissue is 
effective in reducing the rate of tumor 
growth and in prolonging survival of the 
animals. Confirmatory studies have demon-
strated increased longevity in mice with 
Ehrlichll or Krebs69 ascites tumor treated 
with either heparin or a heparinoid. Other 
investigators have not been able to repro-
duce these findings,123, 218 although sig-
nificant decreases in mitotic index136 or in 
percentage of tumor "takes" have been 
reported. 2 , 105 The subcutaneous adminis-
tration of heparin has no effect on the 
primary growth of sarcoma T-241 and sar-
coma DBA49 in mice; metastases are in-
creased markedly in heparin-treated mice 
with the former neoplasm, while metastasis 
formation decreases in mice with sarcoma 
DBA49. 
Increases in tumor growth have been 
reported after treatment with glucuronic 
acid or glucosamine, components of the 
heparin molecule. 105 For this reason hep-
arin inhibitors have been evaluated; partial 
inhibition of growth of Ehrlich ascites tu-
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mor has been reported after treatment with 
mixtures of toluidine blue and protamine 
or toluidine blue, thionine, and ammonium 
chloride but not after treatment with a 
single heparin antagonist. 38 • 40 
The effect of heparin upon suppression 
of tumor metastasis is probably secondary 
to the anticoagulant effect of heparin.2 , 34, 
58, 120 In a study of the incidence of hepatic 
metastases in rats after intraportal injection 
of Walker carcinoma cells, an appreciable 
decrease in incidence of metastatic lesions 
was seen only when heparinization pre-
ceded tumor injection and when heparin 
was continued for 4 to 7 days after in-
jection.58 Heparin has also been reported 
to decrease the number of tumor cells 
circulating in the blood stream,34 although 
this finding has not been confirmed by other 
investigators.12o, 144 
Effect upon wound healing and bone 
repair 
Conflicting reports have appeared con-
cerning effects of heparin upon wound 
healing. Daily injections of heparin bring 
about an increase in the tensile strength of 
wounds in rats 5 days after wounding. This 
increase in tensile strength was over 50 
per cent in each of four experiments, and 
the wounds healed more rapidly than in 
control animals. A further increase in ten-
sile strength was achieved when alternating 
injections of histamine and heparin were 
given.53 Healing of small bums in dogs 
has been accelerated by heparin treat-
ment143 although the experimental design 
was such that the more rapid healing may 
have been due to the influence of secon-
dary wounds on acceleration of healing 
rather than to the effects of heparin per se. 
In well-controlled studies, heparin has in-
creased the survival time of dogs with 
lethal bums and no supportive treatment.48 
Vascular healing is not significantly altered 
by heparin treatment.10 
Heparin treatment of scorbutic guinea 
pigs has been associated with an accelera-
tion of the scorbutic process, producing a 
further decrease in the tensile strength of 
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wounds and increasing the incidence of 
nonunion of fractures.l6l Histologic evi-
dence of a deleterious effect of either hep-
arin or oral anticoagulants upon bone re-
pair in rabbits and dogs195 is in support 
of the premise that inhibition of wound 
healing or bone repair by these agents 
may be related to their anticoagulant effect. 
Since oral anticoagulants appear to have 
an effect similar to that of heparin, com-
petitive inhibition by heparin of mucopoly-
saccharide synthesis seems a less likely 
explanation than the suppression by anti-
coagulants of the development of the fibrin 
matrix upon which fibrous tissue or bone 
is laid down. Daily heparin injection pro-
duces no demonstrable histologic effect 
upon osteogenesis in mice.125 However, 
rabbits receiving a high fat diet and given 
heparin for a prolonged period frequently 
develop spontaneous fractures. 63 Rats on a 
low calcium, high phosphorus diet and 
vitamin D develop rickets, osteoporosis, 
and show a marked increase in tissue mast 
cells.208 When the calvaria of Swiss mice 
are maintained in tissue culture, the addi-
tion of small amounts of heparin or a hep-
arinoid (Treburon) to the medium mark-
edly enhances the amount of bone resorp-
tion obtained with suboptimal concentra-
tions of parathyroid extract, vitamin A, 
or vitamin D 2 , all of which stimulate bone 
resorption; no effect is seen when any of 
these agents is added singly at the same 
concentration. Goldhaber68 speculates that 
heparin functions as a cofactor in stimu-
lating bone resorption. The collagenolytic 
activity of rat bone cell homogenates is 
increased two- to fourfold in animals re-
ceiving large doses of heparin for 10 or 
more days.7 
Several clinical reports have appeared, 
describing spontaneous fractures of verte-
brae and ribs in patients receiving 15,000 
units or more of heparin per day for periods 
greater than 6 months. 75, 97 No deleterious 
effects have been observed in a large series 
of patients receiving 10,000 units or less 
per day for 1 to 15 years. 75 These patients 
have had no alteration in parathyroid 
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function, a normal serum calcium, low 
urinary calcium, and normal excretion 
of hydroxyproline. Griffith and associates 75 
have suggested that, on the basis of 
preliminary observations relating heparin 
effect to a decrease in stability of lyso-
some-like bodies in bone ceIls,225 the 
primary effect of heparin may be at this 
locus, and the bone abnormality seen in 
mast cell disease may be secondary to in-
creased systemic levels of heparin. 
Effect upon diuresis 
Several isolated clinical observations of 
an apparent diuretic effect following hep-
arin injections, the earliest being that of 
Raynaud,171 stimulated subsequent docu-
mentation of this phenomenon. Heparin 
and several heparinoids (N-formyl-chitosan 
polysulfuric acid and xylan polysulfuric 
acid) produce diuresis in humans charac-
terized by an increase in urinary sodium 
and a slight decrease in potassium excre-
tion.146, 185 The heparinoids are less potent 
as diuretics than heparin. The diuretic 
effect of these agents appears only after at 
least 36 hours of therapy and continues 
for several days after heparin is discon-
tinued. The similarities between this pat-
tern of response and that induced by 
amphenone or spirolactones has been 
notedY5 Measurement of aldosterone ex-
cretion in patients receiving a heparinoid 
revealed a reduction in aldosterone excre-
tion (no effect on 17-hydroxycorticoid ex-
cretion) in conjunction with an increase 
in sodium output30, 145, 147, 186, 212; addition 
of spirolactone to this regimen produces 
an appreciable further increase in natri-
uresis. 3o Several highly sulfonated heparin-
oids have natriuretic properties but little 
anticoagulant activity.,sB Schlatmann and 
associates"86 have speculated that the ef-
fect of heparin on natriuresis and aldoste-
rone suppression may be mediated by in-
hibition of the renin-angiotensin system 
which is thought to stimulate aldosterone 
secretion. In support of this theory is the 
finding that heparin complexes with angio-
tensin"o1 and that, although heparin or 
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heparinoids have no effect on aldosterone 
secretion from isolated perfused adrenals, 
they do suppress secretion when admin-
istered to the intact anima1.49 , 64, 213 
A different pattern has been observed 
in both intact and adrenalectomized dogs 
which, within 15 minutes after intravenous 
injection of heparin, develop an appreci-
able increase in urinary potassium without 
a comparable change in sodium output; 
these were short-term experiments lasting 
for 2 hours or less. '55 A comparable effect 
is not seen in humans. '87 In longer-term 
studies in dogs, sodium output in urine 
is increased significantly,lS" 
Heparin appears to inhibit the antidi-
uretic effects of vasopressin when the ef-
fects of vasopressin alone and heparin 
followed by vasopressin are compared in 
water-loaded human subjects.163 
Miscellaneous effects 
Injection of heparin into normal rats 
produces a decrease in nitrogen excretion 
of a magnitude equivalent to the effect 
of 2.5 units of growth hormone; protamine 
produces an increased nitrogen excretion 
and inhibits the action of heparin.71 This 
anabolic effect of heparin could not be con-
firmed in short-term studies (5 days).116 
Heparin activates in the globulin frac-
tion of a serum a substance which inhibits 
the action of human or rat melanocyte-
stimulating hormone on frog skin.lo8 
The color intensity of sulfobromophthal-
ein dye is increased in postheparin serum 
and the absorption peak shifts from 5,800 
to 5,950 Angstrom units; studies were car-
ried out 3 minutes after intravenous in-
jection of 2 to 50 mg. of heparin intra-
venously in normal human males.203 
During the induction of hypothermia in 
dogs, administration of heparin lowers 
"terminal temperature" (the rectal tempera-
ture to which an animal can be cooled 
by surface cooling before the advent of 
ventricular fibrillation or cardiac arrest). 29 
This effect may be secondary to an anti-
thrombotic effect, alteration of suspension 
stability of the blood, or, less likely, to 
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lipoprotein lipase activity in prevention of 
fat embolism. The antithrombotic effect 
seems most likely.140 
Heparin alone or heparin in combination 
with nicotinic acid raises serum iron levels 
in patients with "infectious hyposideremia"; 
this has been explained on the basis of in-
hibition by heparin of the uptake of free 
iron by the reticuloendothelial system. 22 
Phagocytosis of colloidal particles and 
bacteria is also inhibited by heparin and 
other negatively charged macromole-
cules.98, 159 
Injection of a heparinoid (Treburon) 
reduces the period of anesthesia from pen-
tobarbital in dogs, is partially effective 
(significant reduction in time of return of 
righting reHex) in pigeons, and has no 
significant effect on anesthesia in rabbits; 
it has no demonstrable analeptic effect in 
unanesthetized animals.107 
Injection of heparin in rabbits is ac-
companied by a highly significant rise in 
fasting blood sugar which can be prevented 
by prior injection of tolazoline. Heparin 
does not alter hyperglycemic response to 
glucagon or epinephrine but does decrease 
the magnitude of the hypoglycemia in-
duced by insulin. The authors postulate 
that heparin stimulates endogenous release 
of epinephrine.20 Administration of hep-
arin to normal males produces a mean rise 
in blood glucose over that in control sub-
jects of 30 mg. per cent with a peak effect 
at 4 hours.142 
Pulmonary edema produced in dogs by 
intracarotid infusion of massive amounts 
of physiologiC saline is prevented by pre-
treatment with heparin but not pretreat-
ment with oral anticoagulants.H1 
When rats are pretreated with one of a 
number of heparinoids, but not heparin, 
a significant anti-inHammatory effect is 
demonstrable as measured by the zymosan-
edema test.130 
Comment 
The multitude of ancillary effects of a 
pharmacologic agent has seldom evoked 
the interest or documentation that heparin 
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has. This, in itself, is of both theoretical 
and practical interest as a demonstration 
of the many unsuspected side effects which 
may be produced by a drug administered 
to achieve a solitary therapeutic objective. 
In the 30 years of extensive clinical use 
of heparin, reports of undesirable side ef-
fects have been remarkably few. Occa-
sional hemorrhagic complications related 
to its anticoagulant action are inevitable. 
Very rarely, an anaphylactOid response 
following repeated injections has been ob-
served. In recent years, interest has devel-
oped concerning potential deleterious ef-
fects upon bone metabolism of long-term 
administration of relatively large doses of 
heparin. The possibility of development of 
osteoporotic changes after chronic admin-
istration of heparin for 6 months or more 
seems real. 
Several other pharmacologic effects of 
heparin deserve further investigation be-
cause of their potential therapeutic use-
fulness in other areas of human disease. 
The complexing of heparin with many 
cationic macromolecules may be more of 
theoretical than practical value since most 
of the effects described have been observed 
only in vitro. The apparent reduction of 
toxicity of neomycin in vivo without equiv-
alent loss in antibiotic activity may have 
practical utility. The role of heparin and 
heparinoids in reducing experimental peptic 
ulcers is of considerable interest; whether 
this effect is related to complexing with 
pepsin or histamine has not yet been clari-
fied. 
The therapeutic value of heparin in 
certain autoimmune diseases and allergiC 
states is also receiving current attention. 
The natriuretic properties of heparin are 
well documented. Since heparin and re-
lated compounds without appreciable anti-
coagulant activity potentiate the effects of 
other diuretics as well, this action may 
also have therapeutic value. 
If heparin's antiviral action is secondary 
to an inhibition of attachment of virus to 
cell membrane, then this function at an 
extracellular locus provides some ground 
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for hope that it might be effective against 
some viruses in vivo. Its apparent bene-
ficial effect in the treatment of dermatitis 
herpetiformis would support this premise. 
The effect of heparin and plasmin in in-
hibiting tumor implantation and metastasis 
has been under investigation in several 
laboratories; this inhibition is most likely 
secondary to the antithrombotic actions of 
these agents. 
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